To our knowledge, this study is the first analysis after the 2020 NRDL updated to evaluate the health and economic outcomes of dabrafenib plus trametinib treatment as a first-line treatment for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in China. Here, BRAF is linked to metastatic melanoma.